Key clinical point: Adding navitoclax to ruxolitinib improved responses in patients with uncontrolled myelofibrosis and prolonged exposure to ruxolitinib.
Major finding: Overall, 43% of patients had a spleen volume reduction of 35% or greater from baseline, 25% had a reduction in bone marrow fibrosis, and 65% had an improvement in symptoms.
Study details: A phase 2 trial of 34 patients with primary or secondary myelofibrosis.
Disclosures: The trial is sponsored by AbbVie. Dr. Garcia reported relationships with AbbVie, Genentech, and Pfizer.
Garcia JS et al. ASH 2019, Abstract 671.